Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Profile Name||TET2 T1063Nfs*5 TET2 E1207K|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|TET2 T1063Nfs*5 TET2 E1207K||angioimmunoblastic T-cell lymphoma||predicted - sensitive||Dasatinib||Case Reports/Case Series||Actionable||In a Phase I trial, four patients with relapsed/refractory angioimmunoblastic T-cell lymphoma harboring TET2 mutations and/or RHOA G17V achieved a partial response within 30 days of Sprycel (dasatinib) treatment, including one patient harboring TET2 T1063Nfs*5 and TET2 E1207K who maintained the partial response at the time of trial discontinuation (PMID: 32107212).||32107212|